2021
DOI: 10.1097/tp.0000000000003737
|View full text |Cite
|
Sign up to set email alerts
|

Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
46
0
2

Year Published

2021
2021
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 50 publications
(53 citation statements)
references
References 2 publications
5
46
0
2
Order By: Relevance
“…Dhand et al reported encouraging results in SOT patients given bamlanivimab monotherapy or casirivimab/imdevimab without a control group. 4 , 5 Herein, we compared the outcome of SOT patients who were given monoclonal antibodies to an historical control group. According to French law (Loi Jardé), anonymous retrospective studies do not require Institutional Review Board approval.…”
Section: To the Editormentioning
confidence: 99%
“…Dhand et al reported encouraging results in SOT patients given bamlanivimab monotherapy or casirivimab/imdevimab without a control group. 4 , 5 Herein, we compared the outcome of SOT patients who were given monoclonal antibodies to an historical control group. According to French law (Loi Jardé), anonymous retrospective studies do not require Institutional Review Board approval.…”
Section: To the Editormentioning
confidence: 99%
“…Dhand et al reported promising results in 25 solid organ transplant (SOT) patients treated with REIGN-COV2. After a median of 41days of follow up, none of the patients treated with the cocktail was hospitalized dot to COVID-19 [17] .…”
Section: Resultsmentioning
confidence: 99%
“…Clinically, the combination of casirivimab and imdevimab or bamlanivimab and etesevimab reduced the hospitalization rate and emergency department admissions in patients with a mild infection, and risk factors for severe manifestation from COVID-19 [23] , [81] ( Figure 1 , Figure 2 ). [17] , [22] Following these results, the FDA and EMA released a EUA for both the combination of casirivimab and imdevimab and bamlanivimab and etesevimab for mild symptomatic adults with COVID-19 who are not in need of additional oxygen but are at high risk of becoming severely ill. However, monoclonal antibodies are expected to work better in the early infective phase of SARS-CoV2 infection, whereas the late phases are driven by immune dysregulation responsible to severe manifestation in critical patients [82] , [83] .…”
Section: Discussionmentioning
confidence: 99%
“…Regarding therapeutics, the partnership rapidly initiated clinical trials of a repurposed antiviral, remdesivir, that was subsequently shown to be of value in treating patients infected with SARS-CoV-2. 4,5 Working with pharma, Operation Warp Speed also fostered the development of monoclonal antibodies directed against the SARS-CoV-2 spike protein [6][7][8] and encouraged the collection of convalescent plasma, both of which were demonstrated to be of value in the treatment of early COVID-19 infection but of less value in severely ill patients with the disease. 9 In addition, Operation Warp Speed fostered studies of drugs intended to abrogate the cytokine storm associated with severe COVID-19 infection, including interlekin-6 receptor blockers, such as tocilizumab and sarilumab, and Janus kinase inhibitors, such as baracitinib and tofacitinib, though the precise roles for these compounds in the therapy of COVID-19 remains somewhat controversial.…”
Section: What Went Well In the Pandemic Response?mentioning
confidence: 99%